從2000到2025年，全球生物醫(yī)藥產(chǎn)業(yè)走過了不斷探索與進(jìn)步的四分之一個世紀(jì)。

在這25年間，人類逐步讀懂生命“天書”的篇章，精準(zhǔn)醫(yī)療日益走向成熟；世紀(jì)之交，格列衛(wèi)的問世宣告理性藥物設(shè)計與靶向治療時代的到來。與此同時，寡核苷酸、多肽、細(xì)胞與基因療法等創(chuàng)新治療模式持續(xù)涌現(xiàn)，持續(xù)拓展著醫(yī)學(xué)的邊界，也讓越來越多曾被視為“無藥可治”的疾病，迎來了新的治療希望。科研機構(gòu)、產(chǎn)業(yè)力量與資本之間的協(xié)作愈發(fā)緊密，為創(chuàng)新落地不斷匯聚合力。

與此同時，我們也清醒地看到，新藥研發(fā)仍是一條充滿挑戰(zhàn)的道路——研發(fā)周期漫長、投入巨大，可及性與可負(fù)擔(dān)性仍有待提升，且仍有多種疾病尚未被完全攻克。如何讓創(chuàng)新真正惠及更多患者，依然是擺在全球產(chǎn)業(yè)面前的時代命題。也正因為如此，行業(yè)協(xié)作、跨界交流與思想碰撞顯得尤為重要。

誕生于2000年， 藥明康德與全球創(chuàng)新同行，與數(shù)千位合作伙伴一道，既見證行業(yè)的跨越式進(jìn)展，也陪伴產(chǎn)業(yè)穿越周期、穩(wěn)步前行。

2026年1月13日，我們將延續(xù)14年的傳統(tǒng)，于摩根大通醫(yī)療健康大會（J.P. Morgan Healthcare Conference）期間，在舊金山隆重舉辦2026藥明康德全球論壇。

在這個愈發(fā)需要勇氣與協(xié)作的時代，來自全球的投資人、創(chuàng)新者、科研專家以及行業(yè)領(lǐng)袖將齊聚舊金山，共同探討新時代中的機遇與挑戰(zhàn)。群英薈萃、星光璀璨的嘉賓陣容，將為全球醫(yī)藥創(chuàng)新者帶來基于多元背景與不同視角的深度交流與前瞻洞見。

如同往年，藥明康德全球論壇將繼續(xù)實行申請批準(zhǔn)制，向收到確認(rèn)函的嘉賓免費開放。

在舊金山，讓我們再度見證產(chǎn)業(yè)的力量與溫度，并共同堅守那份始終不變的信念：

“讓天下沒有難做的藥，難治的病。”

WuXi Global Forum 2026: Together, We Advance Breakthroughs for Patients

From 2000 to 2025, the global biopharmaceutical industry has undergone a quarter century of continuous exploration and progress.

Over the past 25 years, humanity has gradually learned to read the “book of life,” and precision medicine has steadily matured. At the turn of the century, the launch of Gleevec marked the beginning of an era of rational drug design and targeted therapies. Meanwhile, innovative treatment modalities such as oligonucleotides, peptides, and cell and gene therapies have continued to emerge, expanding the frontiers of medicine and offering new hope to patients with diseases once considered “untreatable.” Collaboration among research institutions, industry stakeholders, and the investment community has also grown closer, creating stronger momentum to translate innovation into real-world impact.

At the same time, we recognize that new drug development remains a highly complex and resource-intensive endeavor—characterized by long development cycles, significant investment requirements, and continuing challenges around access and affordability, while many diseases still lack effective treatment options. How to ensure that innovation benefits a broader patient population remains a key question for the global industry. As such, cross-industry collaboration, open exchange and forward-looking dialogue are more important than ever.

Founded in 2000, WuXi AppTec has advanced in step with global innovators. Together with thousands of partners worldwide, the company has witnessed the industry’s significant breakthroughs while supporting its steady progress through multiple market cycles.

On January 13, 2026, WuXi AppTec will proudly host the 14th WuXi Global Forum in San Francisco, alongside the J.P. Morgan Healthcare Conference—continuing a tradition that has united global leaders for more than a decade.

In an era that increasingly calls for courage and collaboration, investors, innovators, scientific leaders, and industry executives from around the world will gather in San Francisco to explore the opportunities and challenges of a new era.

With a distinguished lineup of world-class speakers, the Forum will bring forward-looking insights and in-depth dialogue to the global biopharmaceutical community, reflecting diverse backgrounds and perspectives across the industry.

As always,the WuXi Global Forum is complimentary and open to innovators across the global ecosystem.

Due to limited space, admission will be by approval only, and entry will be granted to confirmed guests.

In San Francisco, we will once again witness the power and purpose of our industry — and reaffirm the belief that continues to guide us:

“Every drug can be made, and every disease can be treated.”

免責(zé)聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請在「藥明康德」微信公眾號回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。